Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study

Lung, Respiratory and Thoracic Cancer

Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study

J Thorac Oncol

Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ignatius Ou SH, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT

doi: 10.1016/j.jtho.2020.10.007

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Lung Cancer.

Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S

doi: 10.1016/j.lungcan.2019.10.002.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Lung Cancer.

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF

doi: 10.1016/j.lungcan.2019.09.023.

SPECIAL REPORT

Multiple Myeloma (MM)

Traitement du myélome multiple récidivant/réfractaire

Lung, Respiratory and Thoracic Cancer

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Lung Cancer.

Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D

doi: 10.1016/j.lungcan.

Lung, Respiratory and Thoracic Cancer

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Lung Cancer.

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C

doi: 10.1016/j.lungcan.2019.08.010.

Lung, Respiratory and Thoracic CancerLymphoma

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

J Thorac Oncol.

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M

doi: 10.1016/

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

ESMO Open

Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G

doi: 10.1016/j.esmoop.2021.100113

Related content

Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study

Recent Developments in Metastatic Breast Cancer

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Traitement du myélome multiple récidivant/réfractaire

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours